IL286835B2 - Bispecific tetravalent antibodies and methods of makiing and using thereof - Google Patents

Bispecific tetravalent antibodies and methods of makiing and using thereof

Info

Publication number
IL286835B2
IL286835B2 IL286835A IL28683521A IL286835B2 IL 286835 B2 IL286835 B2 IL 286835B2 IL 286835 A IL286835 A IL 286835A IL 28683521 A IL28683521 A IL 28683521A IL 286835 B2 IL286835 B2 IL 286835B2
Authority
IL
Israel
Prior art keywords
heavy chain
bispecific
amino acid
light chain
egfr
Prior art date
Application number
IL286835A
Other languages
English (en)
Hebrew (he)
Other versions
IL286835A (en
IL286835B1 (en
Inventor
Yi Zhu
Gao Zeren
tan Phil
Kovacevich Brian
Renshaw Blair
adamo Jeffrey
Sze Amanda Mak Nga
Zhuo Shi
Chen Lan
Original Assignee
Systimmune Inc
Baili Bio ׂ Chengdu Pharmeceutical Co Ltd
Yi Zhu
Gao Zeren
tan Phil
Kovacevich Brian
Renshaw Blair
adamo Jeffrey
Sze Amanda Mak Nga
Zhuo Shi
Chen Lan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune Inc, Baili Bio ׂ Chengdu Pharmeceutical Co Ltd, Yi Zhu, Gao Zeren, tan Phil, Kovacevich Brian, Renshaw Blair, adamo Jeffrey, Sze Amanda Mak Nga, Zhuo Shi, Chen Lan filed Critical Systimmune Inc
Publication of IL286835A publication Critical patent/IL286835A/en
Publication of IL286835B1 publication Critical patent/IL286835B1/en
Publication of IL286835B2 publication Critical patent/IL286835B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL286835A 2014-12-22 2015-12-19 Bispecific tetravalent antibodies and methods of makiing and using thereof IL286835B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462095348P 2014-12-22 2014-12-22
PCT/US2015/066951 WO2016106157A1 (en) 2014-12-22 2015-12-19 Bispecific tetravalent antibodies and methods of makiing and using thereof

Publications (3)

Publication Number Publication Date
IL286835A IL286835A (en) 2021-10-31
IL286835B1 IL286835B1 (en) 2023-11-01
IL286835B2 true IL286835B2 (en) 2024-03-01

Family

ID=56151464

Family Applications (3)

Application Number Title Priority Date Filing Date
IL286835A IL286835B2 (en) 2014-12-22 2015-12-19 Bispecific tetravalent antibodies and methods of makiing and using thereof
IL305193A IL305193A (en) 2014-12-22 2015-12-19 Bispecific tetravalent antibodies and methods of makiing and using thereof
IL252811A IL252811B (en) 2014-12-22 2017-06-11 Bispecific tetravalent antibodies and methods of makiing and using thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL305193A IL305193A (en) 2014-12-22 2015-12-19 Bispecific tetravalent antibodies and methods of makiing and using thereof
IL252811A IL252811B (en) 2014-12-22 2017-06-11 Bispecific tetravalent antibodies and methods of makiing and using thereof

Country Status (22)

Country Link
US (2) US10919977B2 (enrdf_load_stackoverflow)
EP (3) EP3237005B1 (enrdf_load_stackoverflow)
JP (2) JP6947639B2 (enrdf_load_stackoverflow)
KR (4) KR20250094744A (enrdf_load_stackoverflow)
CN (11) CN106659779B (enrdf_load_stackoverflow)
AU (1) AU2015369831B2 (enrdf_load_stackoverflow)
CA (2) CA3138083A1 (enrdf_load_stackoverflow)
DK (1) DK3237005T3 (enrdf_load_stackoverflow)
ES (2) ES2962675T3 (enrdf_load_stackoverflow)
FI (1) FI3237005T3 (enrdf_load_stackoverflow)
HR (1) HRP20241502T1 (enrdf_load_stackoverflow)
HU (1) HUE069256T2 (enrdf_load_stackoverflow)
IL (3) IL286835B2 (enrdf_load_stackoverflow)
LT (1) LT3237005T (enrdf_load_stackoverflow)
NZ (1) NZ732628A (enrdf_load_stackoverflow)
PL (1) PL3237005T3 (enrdf_load_stackoverflow)
PT (1) PT3237005T (enrdf_load_stackoverflow)
RS (1) RS66070B1 (enrdf_load_stackoverflow)
SG (1) SG11201704741PA (enrdf_load_stackoverflow)
SI (1) SI3237005T1 (enrdf_load_stackoverflow)
SM (1) SMT202400477T1 (enrdf_load_stackoverflow)
WO (2) WO2016106158A1 (enrdf_load_stackoverflow)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3237005T3 (fi) * 2014-12-22 2024-12-02 Systimmune Inc Bispesifisiä tetravalentteja vasta-aineita sekä menetelmiä niiden valmistamiseksi ja käyttämiseksi
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
CN106632681B (zh) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
CN108948195B (zh) * 2017-05-23 2022-05-31 胡毅 一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
CN116925227A (zh) * 2017-06-25 2023-10-24 西雅图免疫公司 抗ror1抗体及其制备和使用方法
SG11202003237QA (en) * 2017-11-02 2020-05-28 Systimmune Inc Bispecific antibodies and methods of making and using thereof
CA3088332A1 (en) * 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against tigit
CN107974461A (zh) * 2018-01-18 2018-05-01 东北农业大学 一种高效表达anti-hEGFR基因的真核表达载体构建方法
CN108220244A (zh) * 2018-01-18 2018-06-29 东北农业大学 一种含重组人表皮生长因子受体抗体基因的cho细胞株、筛选方法及其生产工艺
KR20200143436A (ko) * 2018-04-13 2020-12-23 아피메트 게엠베하 Nk 세포 결합 항체 융합 구조체
US20210115152A1 (en) * 2018-05-16 2021-04-22 Arbele Limited Composition of bispecific antibodies and method of use thereof
JP7193058B2 (ja) * 2018-08-08 2022-12-20 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド Ｃｄ４７およびｈｅｒ２を標的とする組換え二機能性タンパク質
CN110850068B (zh) * 2018-08-21 2023-08-15 上海恒润达生生物科技股份有限公司 一种嵌合抗原受体亲和力检测方法
JP7575100B2 (ja) * 2018-11-13 2024-10-29 ジェイエヌ バイオサイエンシーズ エルエルシー 免疫細胞活性化のための二重特異性抗体
BR112022001329A2 (pt) * 2019-07-26 2022-03-22 Abl Bio Inc Anticorpo biespecífico anti-egfr/anti-4-1bb e uso do mesmo
KR20220058546A (ko) 2019-08-08 2022-05-09 리제너론 파아마슈티컬스, 인크. 신규 항원 결합 분자 포맷
JP2023514371A (ja) * 2020-02-19 2023-04-05 デナリ セラピューティクス インコーポレイテッド 操作された抗ｈｅｒ２二重特異性タンパク質
TWI874613B (zh) * 2020-03-17 2025-03-01 美商西雅圖免疫公司 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
CN111548424A (zh) * 2020-06-05 2020-08-18 上海科弈药业科技有限公司 一种靶向egfr与cd47的多功能融合蛋白及其应用
EP4214238A4 (en) * 2020-09-21 2025-04-09 Systimmune, Inc. EGFR-BINDING COMPLEX AND METHOD FOR THE PREPARATION AND USE THEREOF
KR20240049339A (ko) * 2021-08-25 2024-04-16 시스트이뮨, 인코포레이티드 Egfr 및 her3를 표적으로 하는 이중특이적 4가 항체
EP4405396A2 (en) * 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CN118302192A (zh) * 2021-10-03 2024-07-05 西雅图免疫公司 治疗癌症的方法及其药物组合物
CA3237844A1 (en) * 2021-11-15 2023-05-19 Systimmune, Inc. Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
WO2023241480A1 (zh) * 2022-06-13 2023-12-21 三优生物医药(上海)有限公司 抗pd-l1、vegf和egfr三特异性抗体及其应用
IL319194A (en) * 2022-08-31 2025-04-01 Systimmune Inc BIEPITOPIC TETRAVALENT EGFR-TARGETING ANTIBODY
CN116063564A (zh) * 2022-10-08 2023-05-05 盛禾(中国)生物制药有限公司 一种纯化融合蛋白的方法
CN118829655A (zh) * 2023-02-15 2024-10-22 浙江时迈药业有限公司 Egfr和lag3双靶向的双特异性抗体及其用途
TW202502823A (zh) * 2023-07-07 2025-01-16 大陸商四川科倫博泰生物醫藥股份有限公司 Ｅｇｆｒ／ｃ－ｍｅｔ雙特異性結合蛋白及其用途
WO2025026282A1 (en) * 2023-07-29 2025-02-06 Shanghai Kaijin Biotechnology, Ltd Modified type e multi-specific antibodies
WO2025117871A1 (en) * 2023-11-29 2025-06-05 Systimmune, Inc. Bispecific tetravalent antibody targeting her2 and her3

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100256338A1 (en) * 2009-04-02 2010-10-07 Ulrich Brinkmann Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2014144357A1 (en) * 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2200753B (en) 1986-12-23 1991-01-23 Brookes & Gatehouse Speed measurement device
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1472275B1 (en) * 2002-02-05 2008-12-17 Genentech, Inc. Protein purification
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
UA94213C2 (ru) * 2004-09-17 2011-04-26 Домантис Лимитед Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания
JP2009540015A (ja) * 2006-06-14 2009-11-19 イムクローン・リミテッド・ライアビリティ・カンパニー 抗ｅｇｆｒ抗体の凍結乾燥製剤
AU2007353412A1 (en) * 2006-11-21 2008-11-20 Fox Chase Cancer Center Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
CN104447995A (zh) * 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
AU2010229705A1 (en) 2009-03-27 2011-10-20 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
SG175081A1 (en) * 2009-04-07 2011-11-28 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
UY32870A (es) * 2009-09-01 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US10208128B2 (en) * 2009-11-04 2019-02-19 Affibody Ab HER3 binding polypeptides
WO2012044612A1 (en) * 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her3 antibodies
CA2817448C (en) 2010-12-23 2019-01-22 F. Hoffmann-La Roche Ag Binding agent
TWI671315B (zh) 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012143523A1 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
US20140170148A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
EP2703486B1 (en) * 2011-04-25 2018-03-07 Daiichi Sankyo Company, Limited Anti-b7-h3 antibody
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
CN102250247B (zh) 2011-06-15 2013-06-19 常州亚当生物技术有限公司 一种抗vegf/ang2双特异性抗体及其应用
ES2628075T3 (es) * 2011-12-19 2017-08-01 Synimmune Gmbh Molécula de anticuerpo biespecífica
WO2013096346A1 (en) 2011-12-22 2013-06-27 Development Center For Biotechnology Bispecific t-cell activator antibody
CN104220457A (zh) * 2012-03-27 2014-12-17 霍夫曼-拉罗奇有限公司 涉及her3抑制剂的诊断和治疗
WO2014012082A2 (en) * 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs
LT2922872T (lt) * 2012-11-21 2018-12-27 Janssen Biotech, Inc. Bispecifiniai egfr/c-met antikūnai
CN103333179B (zh) * 2012-12-21 2017-06-16 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
US9388243B2 (en) * 2013-05-29 2016-07-12 Samsung Electronics Co., Ltd. Method of target membrane protein depletion
FI3237005T3 (fi) * 2014-12-22 2024-12-02 Systimmune Inc Bispesifisiä tetravalentteja vasta-aineita sekä menetelmiä niiden valmistamiseksi ja käyttämiseksi

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100256338A1 (en) * 2009-04-02 2010-10-07 Ulrich Brinkmann Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2014144357A1 (en) * 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies

Also Published As

Publication number Publication date
CN117467017A (zh) 2024-01-30
CN113105553A (zh) 2021-07-13
JP2021119149A (ja) 2021-08-12
EP4491195A2 (en) 2025-01-15
EP3237006A4 (en) 2018-05-30
CA2969867C (en) 2022-01-25
EP3237006A1 (en) 2017-11-01
IL305193A (en) 2023-10-01
LT3237005T (lt) 2024-11-11
CN113105551A (zh) 2021-07-13
CN113105552A (zh) 2021-07-13
JP7335290B2 (ja) 2023-08-29
CA3138083A1 (en) 2016-06-30
DK3237005T3 (en) 2024-11-18
CN106659779B (zh) 2021-05-18
CN107206074A (zh) 2017-09-26
HRP20241502T1 (hr) 2025-01-03
US20170369587A1 (en) 2017-12-28
RS66070B1 (sr) 2024-11-29
US10919977B2 (en) 2021-02-16
CN113512120A (zh) 2021-10-19
AU2015369831B2 (en) 2019-07-11
CN113512123A (zh) 2021-10-19
EP4491195A3 (en) 2025-04-02
CN113512121A (zh) 2021-10-19
SI3237005T1 (sl) 2025-02-28
IL286835A (en) 2021-10-31
US10717783B2 (en) 2020-07-21
KR20170091162A (ko) 2017-08-08
WO2016106158A1 (en) 2016-06-30
CN113512122B (zh) 2024-09-10
NZ732628A (en) 2019-01-25
SG11201704741PA (en) 2017-07-28
KR20230149328A (ko) 2023-10-26
US20170073418A1 (en) 2017-03-16
FI3237005T3 (fi) 2024-12-02
PT3237005T (pt) 2024-11-18
WO2016106157A1 (en) 2016-06-30
ES2995733T3 (en) 2025-02-11
CN113512121B (zh) 2024-10-25
CN106659779A (zh) 2017-05-10
KR102548827B1 (ko) 2023-06-30
KR20250094744A (ko) 2025-06-25
CN113105551B (zh) 2024-10-25
EP3237005B1 (en) 2024-09-18
HUE069256T2 (hu) 2025-02-28
IL252811A0 (en) 2017-08-31
SMT202400477T1 (it) 2025-01-14
KR102823201B1 (ko) 2025-06-23
CN113150165A (zh) 2021-07-23
IL252811B (en) 2021-10-31
CN107206074B (zh) 2023-12-01
KR102590385B1 (ko) 2023-10-18
CA2969867A1 (en) 2016-06-30
EP3237006B1 (en) 2023-08-16
AU2015369831A1 (en) 2017-06-29
CN113512123B (zh) 2024-10-25
JP6947639B2 (ja) 2021-10-13
ES2962675T3 (es) 2024-03-20
CN113512122A (zh) 2021-10-19
JP2018509175A (ja) 2018-04-05
EP3237005A1 (en) 2017-11-01
CN113105552B (zh) 2024-09-20
EP3237005A4 (en) 2018-05-23
CN113105553B (zh) 2024-09-10
CN113512120B (zh) 2024-08-02
IL286835B1 (en) 2023-11-01
PL3237005T3 (pl) 2025-01-27
CN113150165B (zh) 2024-09-03
KR20230104988A (ko) 2023-07-11

Similar Documents

Publication Publication Date Title
JP7335290B2 (ja) 二重特異性四価抗体並びにその製作及び使用方法
US10669339B2 (en) Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
US20170044259A1 (en) Anti-pd1 antibodies, activatable anti-pd1 antibodies, and methods of use thereof
JP2023531042A (ja) ４－１ｂｂ結合タンパク質及びその用途
Zuo et al. A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding
US20210277128A1 (en) Bispecific Tetravalent Antibodies and Methods of Making and Using Thereof
TW202146446A (zh) 一種抗pd-l1和egfr的四價雙特異性抗體
HK1233941A1 (en) Bispecific tetravalent antibodies and methods of making and using thereof
HK1233941B (zh) 双特异性四价抗体及其制造和使用方法
EA039736B1 (ru) Анти-pdl1-антитела, активируемые анти-pdl1-антитела и способы их применения